Global Continuous Glucose Monitoring Devices Market

Continuous Glucose Monitoring Devices Market Size, Share, Growth Analysis, By Component (Transmitters, Sensors), By Connectivity (Bluetooth, 4G), By End-use (Hospitals, Homecare), By Region - Industry Forecast 2026-2033

Report ID: SQMIG35A2568 | Region: Global | Published Date: December, 2025
Pages: 219 |Tables: 63 |Figures: 75

To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt

    • FAQs

    Continuous Glucose Monitoring Devices Market size was valued at USD 9.84 Billion in 2024 and is poised to grow from USD 11.17 Billion in 2025 to USD 30.76 Billion by 2033, growing at a CAGR of 13.5% during the forecast period (2026–2033).

    The competitive landscape of the global continuous glucose monitoring devices market is characterized by intense rivalry among key players aiming to capture a significant share. Industry leaders like Abbott, Dexcom, and Medtronic maintain dominant positions owing to their extensive product portfolios, technological innovation, and established market presence. These companies continuously invest in research and development to enhance device accuracy, user-friendliness, and connectivity. 'Abbott Laboratories (USA)', 'Dexcom, Inc. (USA) ', 'Medtronic PLC (Ireland) ', 'Roche (Switzerland) ', 'Senseonics Holdings, Inc. (USA) ', 'GlySens Incorporated (USA) ', 'Novo Nordisk A/S (Denmark) ', 'Insulet Corporation (USA) ', 'Tandem Diabetes Care, Inc. (USA) ', 'Ascensia Diabetes Care Holdings AG (Switzerland) ', 'Ypsomed AG (Switzerland) ', 'A. Menarini Diagnostics (Italy) ', 'Nemaura Medical Inc. (UK) ', 'Medisana GmbH (Germany) ', 'Sanofi (France) ', 'Johnson & Johnson (USA) ', 'B. Braun Melsungen AG (Germany) ', 'Arkray, Inc. (Japan) ', 'Terumo Corporation (Japan) ', 'MicroTech Medical (China)'

    The increasing global prevalence of diabetes is a significant driver, necessitating effective monitoring and management solutions like continuous glucose monitoring devices.

    Integration with Digital Health Platforms: Continuous glucose monitoring devices are increasingly being integrated with digital health platforms, allowing users to track and manage their data seamlessly alongside other health metrics.

    Expected to capture the leading market share of 38.9% in 2022, the North American region is poised to maintain its preeminence throughout the projected period. This region's growth trajectory is propelled by the mounting prevalence of diabetes and proactive endeavors undertaken by national governments to address the challenge on a broader scale.

    Related Reports

    Blood Glucose Monitoring Devices Market
    Buy Now GET FREE SAMPLE
    Diabetes Care Devices Market
    Buy Now GET FREE SAMPLE
    Diabetes Device Market
    Buy Now GET FREE SAMPLE
    Point-of-care Glucose Testing Market
    Buy Now GET FREE SAMPLE
    Blood Glucose Test Strips Market
    Buy Now GET FREE SAMPLE
    Diabetes Care Devices and Drugs Market
    Buy Now GET FREE SAMPLE
    Glucose Tolerance Test Market
    Buy Now GET FREE SAMPLE
    Insulin Storage Devices Market
    Buy Now GET FREE SAMPLE

    Feedback From Our Clients

    Global Continuous Glucose Monitoring Devices Market

    Report ID: SQMIG35A2568

    $5,300
    BUY NOW